{"entity":{"id":"nct06492005","kind":"trial","name":"A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer","aka":[],"tldr":"A phase 2 trial of 9MW2821 in triple-negative breast cancer, run by Mabwell (Shanghai) Bioscience Co., Ltd., now recruiting.","summary":"A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer is a phase 2 interventional study registered as NCT06492005 by Mabwell (Shanghai) Bioscience Co., Ltd., with 160 participants planned, started 2024-07-26 and due to reach its primary completion in 2026-07. Interventions recorded: 9MW2821 and PD-1 inhibitior.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06492005","url":"https://clinicaltrials.gov/study/NCT06492005"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06492005","phase":"2","setting":"A Phase II Clinical Study of Efficacy and Safety of 9MW2821Monotherapy or Combined With PD-1 Inhibitor in Locally Advanced or Metastatic Triple-Negative Breast Cancer","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","enrolled":160,"outcomes":[]},"route":"/trials/nct06492005/","neighbours":{"cancer":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}]}}